|
The
company's stock rose about 1.4 percent $112.50 in premarket
trading, on track to open at a record high.
J&J's first-quarter sales rose 0.6 percent to $17.48 billion,
led by demand for pharmaceutical products in the United States.
Overall, though, sales were constrained by the strong dollar and
Venezuela's currency devaluation.
Net earnings fell to $4.29 billion, or $1.54 per share, from
$4.32 billion, or $1.53 per share, a year earlier.
Excluding special items, the company earned $1.68 per share,
compared with the average analysts' estimate of $1.65, according
to Thomson Reuters I/B/E/S.
J&J said that based on current exchange rates, it now expected
sales of $71.2 billion to $71.9 billion in 2016, up from its
January forecast of $70.8 billion to $71.5 billion.
On an adjusted basis, it said it expected to earn $6.53-$6.68
per share for the year, up from its prior estimate of
$6.43-$6.58.
The company's pharmaceutical unit accounted for 45 percent of
its $70 billion in sales last year. Medical devices made up for
more than a third of sales, with over-the-counter medicines and
other consumer products making up the rest.
(Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb
Chakrabarty and Ted Kerr)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
